Journal of Nepal Medical Association (Jul 2021)

Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

  • Gentle Sunder Shrestha,
  • Bidesh Bista,
  • Ashesh Dhungana,
  • Nimesh Poudel,
  • Shraddha Bhattarai,
  • Manjit Shrestha,
  • Sandip Bhandari,
  • Binit Vaidya

DOI
https://doi.org/10.31729/jnma.6680
Journal volume & issue
Vol. 59, no. 238

Abstract

Read online

Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.

Keywords